{"id":"W2954226397","doi":"10.1182/blood.2019003127","title":"Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Takeda Oncology","keywords":"ABVD; Dacarbazine; Brentuximab vedotin; Medicine; Vinblastine; Bleomycin; Internal medicine; Chemotherapy regimen; Population; Progression-free survival; Nuclear medicine; Oncology; Surgery; Chemotherapy; Lymphoma; Vincristine; Hodgkin lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009379024,0.0001915624,0.0004178012,0.00002206603,0.00006945847,0.00001644731,0.0001485212,0.00005522832,0.00005847981],"category_scores_gemma":[0.00002971543,0.0001070789,0.0001495276,0.0001865696,0.00006682028,0.00002945364,0.00005503047,0.00005108969,0.00001138003],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004201706,"about_ca_system_score_gemma":0.0001840273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003226539,"about_ca_topic_score_gemma":0.00001701975,"domain_scores_codex":[0.9988366,0.00003800311,0.0002459031,0.0003254288,0.0003123976,0.0002416024],"domain_scores_gemma":[0.9992383,0.00006470653,0.0001246794,0.0003742716,0.00007132391,0.0001267817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00493798,0.04849818,0.9151331,0.0002880619,0.003193561,0.0001751449,0.003830913,0.000005450346,0.003351785,0.00121932,0.004861221,0.01450528],"study_design_scores_gemma":[0.2285219,0.00984441,0.5853558,0.0001545825,0.002144725,0.0000357722,0.001989283,0.0001532936,0.1558122,0.00003195929,0.01557452,0.0003815259],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918894,0.0001286372,0.00004334421,0.005775822,0.00003959134,0.001626552,0.00005240611,0.00004559506,0.0003987018],"genre_scores_gemma":[0.9975954,0.00002561766,0.0007587461,0.001101812,0.0001297073,0.0001481039,0.0000141845,0.00003678539,0.0001895903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3297774,"threshold_uncertainty_score":0.436655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01647671811408724,"score_gpt":0.2523826619715569,"score_spread":0.2359059438574697,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}